Elmind Capital LP Buys New Shares in Vera Therapeutics, Inc. $VERA

Elmind Capital LP bought a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 482,500 shares of the company’s stock, valued at approximately $24,434,000. Vera Therapeutics makes up 7.2% of Elmind Capital LP’s investment portfolio, making the stock its 4th largest holding.

Several other large investors have also made changes to their positions in the business. Price T Rowe Associates Inc. MD lifted its position in shares of Vera Therapeutics by 49.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after acquiring an additional 1,795,537 shares in the last quarter. Deerfield Management Company L.P. lifted its position in shares of Vera Therapeutics by 8.8% in the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after acquiring an additional 293,040 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Vera Therapeutics by 11.9% in the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after acquiring an additional 379,748 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after acquiring an additional 600,000 shares in the last quarter. Finally, Eversept Partners LP lifted its position in shares of Vera Therapeutics by 9.4% in the fourth quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock valued at $155,581,000 after acquiring an additional 264,468 shares in the last quarter. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total value of $679,690.00. Following the sale, the chief executive officer directly owned 216,744 shares of the company’s stock, valued at approximately $7,963,174.56. The trade was a 7.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Vera Therapeutics Trading Up 4.0%

Shares of VERA stock opened at $35.01 on Thursday. Vera Therapeutics, Inc. has a 12-month low of $19.07 and a 12-month high of $56.05. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The stock’s 50-day moving average price is $36.63 and its 200-day moving average price is $41.52. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.32 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the previous year, the company earned ($0.81) earnings per share. Equities research analysts predict that Vera Therapeutics, Inc. will post -6.23 EPS for the current fiscal year.

Analysts Set New Price Targets

VERA has been the topic of several research analyst reports. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. The Goldman Sachs Group restated a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. Finally, Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective on the stock in a research report on Wednesday, March 11th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $78.00.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.